• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    A Presidio Property Trust Major Investment To Be Part of Russell 2000®

    5/29/24 4:21:47 PM ET
    $CDT
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate
    Get the next $CDT alert in real time by email

    SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ:SQFT, SQFTP, SQFTW))) ("Presidio" or the "Company"), an internally managed, diversified real estate investment trust ("REIT"), has announced that Conduit Pharmaceuticals Inc. (NASDAQ:CDT, CDTTW))) ("Conduit"), of which the Company owns approximately 6.3%, is expected to be added to the Russell 2000 Index effective at the open of US equity markets on Monday, July 1, 2024, as part of the annual reconstitution of the Russell stock indexes. A preliminary list of index additions, including Conduit, was posted by FTSE Russell on May 24, 2024.

    The annual Russell US Indexes reconstitution captures the largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

    "We are excited the additional visibility that being in the Russell 2000 and Russell 3000 will give Conduit," said Jack Heilbron, President and Chief Executive Officer of Presidio.

    Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of December 2023, about $10.5 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, a prominent global index provider.

    About Presidio Property Trust

    Presidio is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. Our office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California. While geographical clustering of real estate enables us to reduce our operating costs through economies of scale by servicing several properties with less staff, it makes us susceptible to changing market conditions in these discrete geographic areas, including those that have developed as a result of COVID-19. Presidio owns approximately 6.5% of the outstanding common stock of Conduit Pharmaceuticals Inc., a disease agnostic multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development. For more information on Presidio, please visit the Company's website at https://www.PresidioPT.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains statements that are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. Forward-looking statements are statements that are not historical, including statements regarding management's intentions, beliefs, expectations, representations, plans or predictions of the future, and are typically identified by such words as "believe," "expect," "anticipate," "intend," "estimate," "may," "will," "should" and "could." Forward-looking statements regarding the Company include, but are not limited to, statements regarding the Russell 3000® Index reconstitution, including the anticipated timing of Conduit's inclusion in the Russell 3000® Index and the potential benefits of such inclusion. Because such statements include risks, uncertainties and contingencies, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's present expectations, but these statements are not guaranteed to occur. Except as required by law, the Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes. Investors should not place undue reliance upon forward-looking statements. For further discussion of the factors that could affect outcomes please refer to the Company's filings with the SEC, including those under "Risk Factors" therein, copies of which are available on the SEC's website, www.sec.gov.

    Investor Relations Contact:

    Presidio Property Trust, Inc.

    Lowell Hartkorn, Investor Relations

    [email protected]

    Telephone: (760) 471-8536 x1244



    Primary Logo

    Get the next $CDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDT
    $SQFT

    CompanyDatePrice TargetRatingAnalyst
    Presidio Property Trust Inc.
    $SQFT
    11/15/2021$6.00 → $5.50Buy
    Aegis Capital
    Presidio Property Trust Inc.
    $SQFT
    7/28/2021$6.00Buy
    Aegis Capital
    More analyst ratings

    $CDT
    $SQFT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CDT Notes Sarborg Publication of PRISM Framework Expanding AI

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the publication of its research paper titled "PRISM: cross-species connectivity mapping of plant intervention and stress signatures for translational agriculture." CDT holds a 20% equity interest in Sarborg and believes this development represents a meaningful extension of Sarborg's proprietary Signature Intelligence platform beyond its initial pharmaceutical focus into the agrichemical and broader industrial biology sectors. PRISM represents a novel framework for applying connectivity mapping to

    4/7/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the filing of two new patent applications that further expand the Company's intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis. The first newly filed patent covers a combination therapy pairing tapinarof with a class of drugs clinically proven in psoriasis and atopic dermatitis, while the second patent relates to novel cocrystal forms of tapinarof with these agents. CDT believes these developments may underpin a second-generation tapinarof product with enhance

    3/26/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Inc. Announces Reverse Stock Split

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effective on March 26, 2026, at 5:00 pm, Eastern Time (the "Effective Time"), and the Company's common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market ("Nasdaq") at market open under the existing

    3/25/26 8:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    $SQFT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Heilbron Jack Kendrick bought $28,200 worth of Common Stock - Series A (10,000 units at $2.82) (SEC Form 4)

    4 - Presidio Property Trust, Inc. (0001080657) (Issuer)

    12/30/25 11:39:41 AM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    Chief Executive Officer Heilbron Jack Kendrick bought $14,780 worth of Preferred Stock - Series D (1,000 units at $14.78) (SEC Form 4)

    4 - Presidio Property Trust, Inc. (0001080657) (Issuer)

    12/30/25 11:38:42 AM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    Chief Executive Officer Heilbron Jack Kendrick bought $32,900 worth of Common Stock - Series A (10,000 units at $3.29) (SEC Form 4)

    4 - Presidio Property Trust, Inc. (0001080657) (Issuer)

    12/30/25 11:36:40 AM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    $CDT
    $SQFT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Heilbron Jack Kendrick

    4 - Presidio Property Trust, Inc. (0001080657) (Issuer)

    4/13/26 4:31:47 PM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    SEC Form 4 filed by Durfey James Robert

    4 - Presidio Property Trust, Inc. (0001080657) (Issuer)

    4/13/26 4:24:22 PM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    SEC Form 4 filed by Taylor Mark Andrew

    4 - CDT Equity Inc. (0001896212) (Issuer)

    3/30/26 9:23:30 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDT
    $SQFT
    SEC Filings

    View All

    SEC Form 424B5 filed by CDT Equity Inc.

    424B5 - CDT Equity Inc. (0001896212) (Filer)

    4/2/26 4:15:35 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by CDT Equity Inc.

    NT 10-K - CDT Equity Inc. (0001896212) (Filer)

    4/1/26 4:01:02 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presidio Property Trust Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Presidio Property Trust, Inc. (0001080657) (Filer)

    3/27/26 8:21:47 PM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    $CDT
    $SQFT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on Presidio Property Trust with a new price target

    Aegis Capital reiterated coverage of Presidio Property Trust with a rating of Buy and set a new price target of $5.50 from $6.00 previously

    11/15/21 10:14:14 AM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    Aegis Capital initiated coverage on Presidio Property Trust with a new price target

    Aegis Capital initiated coverage of Presidio Property Trust with a rating of Buy and set a new price target of $6.00

    7/28/21 9:45:36 AM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    $CDT
    $SQFT
    Financials

    Live finance-specific insights

    View All

    CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures

    2/20/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Increases Bitcoin Holding

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the acquisition of 9.25648743 Bitcoin ("BTC") for an aggregate purchase price of $1,005,000 (gross of fees), at an average acquisition price of $108,301.75 per BTC. Following this transaction, CDT's total Bitcoin holdings now stand at 17.9090111 BTC. This acquisition marks a continued execution of CDT's cryptocurrency treasury reserve strategy, aimed at diversifying the Company's balance sheet and enhancing long-term shareholder value through the prudent accumulation of digital assets. "CDT remains committed to strategically deploying capita

    10/17/25 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presidio Property Trust Announces Series D Preferred Stock Cash Dividend

    SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:SQFT, SQFTP, SQFTW)) Presidio Property Trust, Inc. ("Presidio" or the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today announced that its Board of Directors has authorized, and the Company has declared, a dividend on its 9.375% Series D Cumulative Redeemable Perpetual Preferred Stock (the "Series D Preferred Stock") for the months of July 2025, August 2025 and September 2025. In accordance with the terms of the Series D Preferred Stock, the July 2025 Series D dividend will be payable in cash in the amount of $0.19531 per share on August 15, 2025, to shareholders of record of Series D Pref

    7/8/25 4:15:00 PM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    $CDT
    $SQFT
    Leadership Updates

    Live Leadership Updates

    View All

    Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

    Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors. Mr. Fry has over 30 years' experience in investment banking having held senior executive positions at various top-tier in

    11/19/24 4:30:00 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Conduit Pharmaceuticals to Join Russell 3000® Index

    SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat

    6/13/24 8:00:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presidio Property Trust Reaches Agreement With Zuma Capital Management Appoints Elena Piliptchak to Board of Directors

    SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. ("Presidio" or the "Company"), an internally managed, diversified real estate investment trust ("REIT"), announced today that it has entered into a cooperation agreement with Zuma Capital Management, LLC ("Zuma"), Ouray Capital Management, LLC ("Ouray"), Reuben Berman, Stefani Carter, Vito Garfi, Brent Morrison, Elena Piliptchak, and certain affiliated and associated persons thereof (collectively, the "Zuma Investor Group") that beneficially holds, in the aggregate, 1,103,655 shares, or approximately 7.6%, of Presidio's outstanding common stock. Under the terms of the cooperation agreement, Elena Piliptchak, the

    5/10/24 8:45:00 AM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    $CDT
    $SQFT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Presidio Property Trust Inc.

    SC 13G/A - Presidio Property Trust, Inc. (0001080657) (Subject)

    11/14/24 5:16:03 PM ET
    $SQFT
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    11/6/24 6:01:49 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Conduit Pharmaceuticals Inc.

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    10/18/24 4:15:06 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care